Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1997 2
1998 1
2000 1
2003 1
2008 1
2009 3
2012 2
2013 1
2015 1
2016 3
2017 2
2019 1
2020 2
2021 3
2022 6
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
Alloreactivity: an old puzzle revisited.
Nagy ZA. Nagy ZA. Scand J Immunol. 2012 May;75(5):463-70. doi: 10.1111/j.1365-3083.2012.02680.x. Scand J Immunol. 2012. PMID: 22229944 Free article. Review.
Tooth discolouration: staining effects of various sealers and medicaments.
Thomson AD, Athanassiadis B, Kahler B, Walsh L. Thomson AD, et al. Aust Endod J. 2012 Apr;38(1):2-9. doi: 10.1111/j.1747-4477.2011.00339.x. Aust Endod J. 2012. PMID: 22432819
The roots were filled with either Multi-Cal (Pulpdent Corporation, Watertown, MA, USA), Ledermix (Lederle Laboratories, Wolfratshausen, Germany), 2% chlorhexadine acetate in polyethylene glycol (PEG), 5% clindamycin in PEG, PEG alone (as a vehicle control), sealers AH26 (D …
The roots were filled with either Multi-Cal (Pulpdent Corporation, Watertown, MA, USA), Ledermix (Lederle Laboratories, Wolfratshausen …
Favorable impact of therapy management by an interactive eHealth system on severe adverse events in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapy.
Harbeck N, Kates R, Schinköthe T, Schumacher J, Wuerstlein R, Degenhardt T, Lüftner D, Räth P, Hoffmann O, Lorenz R, Decker T, Reinisch M, Göhler T, Staib P, Gluz O, Fasching PA, Schmidt M; AGO-B, WSG PreCycle investigators. Harbeck N, et al. Cancer Treat Rev. 2023 Dec;121:102631. doi: 10.1016/j.ctrv.2023.102631. Epub 2023 Oct 18. Cancer Treat Rev. 2023. PMID: 37862832 Review.
Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial.
Harbeck N, Fasching PA, Wuerstlein R, Degenhardt T, Lüftner D, Kates RE, Schumacher J, Räth P, Hoffmann O, Lorenz R, Decker T, Reinisch M, Göhler T, Staib P, Gluz O, Schinköthe T, Schmidt M; AGO-B WSG PreCycle investigators (see Appendix 1). Harbeck N, et al. Ann Oncol. 2023 Aug;34(8):660-669. doi: 10.1016/j.annonc.2023.05.003. Epub 2023 May 16. Ann Oncol. 2023. PMID: 37201751 Free article. Clinical Trial.
PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant.
Degenhardt T, Fasching PA, Lüftner D, Müller V, Thomssen C, Schem C, Witzel I, Decker T, Tesch H, Kümmel S, Uleer C, Wuerstlein R, Hoffmann O, Warm M, Marschner N, Schinköthe T, Kates RE, Schumacher J, Otremba B, Zaiss M, Harbeck N, Schmidt M; PreCycle Investigators. Degenhardt T, et al. Trials. 2023 May 17;24(1):338. doi: 10.1186/s13063-023-07306-z. Trials. 2023. PMID: 37198674 Free PMC article. Clinical Trial.
Improvement of dynamic venous function after thermal ablation with steam vein occlusion - 6-weeks and 1-year follow-up after 167 treatments.
Konschake W, Tembulatow M, Lutze S, Arnold A, Jünger M, Riebe H. Konschake W, et al. Clin Hemorheol Microcirc. 2022;80(3):291-305. doi: 10.3233/CH-211239. Clin Hemorheol Microcirc. 2022. PMID: 34864648
METHODS: The venous drainage and the venous refilling time (T0) of the leg treated were determined by photoplethysmography (Elcat, Wolfratshausen, Germany) before, six weeks and one year after the intervention to examine the effects on global venous function. ...
METHODS: The venous drainage and the venous refilling time (T0) of the leg treated were determined by photoplethysmography (Elcat, Wolfra …
Association between somatic symptom disorder and symptoms with daily life impairment after SARS-CoV-2 infection - results from a population-based cross-sectional study.
Schneider A, Huber L, Lohse J, Linde K, Greissel A, Sattel H, Henningsen P, Hapfelmeier A. Schneider A, et al. J Psychosom Res. 2023 May;168:111230. doi: 10.1016/j.jpsychores.2023.111230. Epub 2023 Mar 13. J Psychosom Res. 2023. PMID: 36933364 Free PMC article.
A symptom questionnaire, including the scales Patient Health Questionnaire PHQ-15 (somatisation module), SSD-12 (psychological distress in SSD), PHQ-2 (depression), GAD-2 (anxiety), and FAS (fatigue assessment scale) was sent in 02/2022 to all adult residents of the district Bad …
A symptom questionnaire, including the scales Patient Health Questionnaire PHQ-15 (somatisation module), SSD-12 (psychological distress in S …
Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure.
Dietz J, Müllhaupt B, Buggisch P, Graf C, Peiffer KH, Matschenz K, Schattenberg JM, Antoni C, Mauss S, Niederau C, Discher T, Trauth J, Dultz G, Schulze Zur Wiesch J, Piecha F, Klinker H, Müller T, Berg T, Neumann-Haefelin C, Berg CP, Zeuzem S, Sarrazin C; German HCV Resistance Study Group; University Hospitals; Academic Hospitals; Local study sites (private practices), Germany. Dietz J, et al. J Hepatol. 2023 Jan;78(1):57-66. doi: 10.1016/j.jhep.2022.08.016. Epub 2022 Aug 27. J Hepatol. 2023. PMID: 36031158
The relationship of intracanal medicaments to postoperative pain in endodontics.
Ehrmann EH, Messer HH, Adams GG. Ehrmann EH, et al. Int Endod J. 2003 Dec;36(12):868-75. doi: 10.1111/j.1365-2591.2003.00735.x. Int Endod J. 2003. PMID: 14641427 Clinical Trial.
The canals were dried and one of the following three medicaments was inserted into the canal in random sequence: Group 1: Ledermix paste (Lederle Pharmaceuticals, Division of Cyanamid, Wolfratshausen, Germany); Group 2: calcium hydroxide paste (Calcipulpe, Septodont, Franc …
The canals were dried and one of the following three medicaments was inserted into the canal in random sequence: Group 1: Ledermix paste (Le …
35 results